CJC-IPA Blend (CJC-1295/ Ipamorelin) – 10mg

The CJC-IPA Blend combines CJC-1295 and Ipamorelin into a single 10mg lyophilized vial. The most extensively researched and frequently referenced dual peptide combination in growth hormone secretagogue literature. Hudson Science’s formulation delivers both compounds in a single reconstitute preparation, eliminating the separate reconstitution and administration steps required when sourcing each compound individually and supporting consistent co administration ratios across extended research protocols.

The pharmacological rationale behind this specific combination is grounded in the complementary and synergistic mechanisms of the two components. CJC-1295 is a GHRH analogue that binds pituitary GHRH receptors, stimulating endogenous GH secretion in a physiologically regulated pulsatile pattern. Its Drug Affinity Complex (DAC) modification enabling albumin binding that extends its half-life to approximately 6–8 days, sustaining continuous GHRH receptor stimulation between administrations. Ipamorelin is a selective GHS-R1a agonist that stimulates GH release through a completely separate receptor pathway. It can directly activate pituitary somatotroph cells while simultaneously suppressing hypothalamic somatostatin tone, the inhibitory signal that limits GH pulse amplitude. The combination of sustained GHRH receptor stimulation from CJC-1295 and somatostatin suppression with direct somatotroph activation from Ipamorelin produces a synergistic GH secretory response substantially exceeding either compound administered alone, the most documented synergistic interaction in GHRH and GHRP combination research.

Ipamorelin’s exceptional GHS-R1a selectivity is the specific reason it is the preferred GHRP partner for CJC-1295 in this blend. Where GHRP-2 and Hexarelin produce dose dependent cortisol and prolactin elevation alongside GH secretion, Ipamorelin’s documented minimal effect on cortisol, prolactin, ACTH, and aldosterone at research relevant doses means the combined GH response from this blend is attributable primarily to the synergistic GHRH and GHS-R1a pathway co activation. Without secondary hormonal variables that less selective GHRPs would introduce into the research endpoint analysis.

Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity across both peptide components before being made available, with COA documentation available on request. CSD stocks CJC-1295 and Ipamorelin both as this combined blend and as individual standalone compounds, giving researchers the flexibility to source the pre combined format for convenience or individual compounds for custom ratio protocols from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched in GH axis stimulation, anti ageing, and body composition research contexts. Browse CSD’s full peptide range for complete sourcing.